Human Genome Sciences, Inc. (HGSI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Human Genome Sciences, Inc. (HGSI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bill small who wrote (5)	7/18/1996 9:45:00 PM
From: Andrew G.	of 1127

HGSI investors, where are you? HGSI is flying!!! Bills comment about HGSI being undervalued at $30 must have been overheard on Wall Street. Today HGSI closed at 37.375 up 4.375 from yesterdays close of 33.125 which was also up 5.625. Is there no stopping this high flyer. The news below should certainly help next quarters earnings! Wall Street Journal -- July 17, 1996 Health: Genome Technology Agreement ROCKVILLE, Md. -- Human Genome Sciences Inc. and Britain's SmithKline Beecham PLC agreed to collaborate with Germany's Merck KGaA to discover pharmaceuticals using genomic technology, the companies said. SmithKline and Merck KGaA, which isn't related to the U.S.-based pharmaceutical giant Merck & Co., will collaborate on developing and marketing some products discovered using the genomic technology. Merck KGaA will also make licensing-fee and product-development milestone payments to SmithKline and Human Genome Sciences. Excluding the milestone payments and royalties, Merck KGaA will make payments totaling $50 million during the initial term of the collaboration.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next